Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function

Author:

Saxena Varun1,Koraishy Farrukh M.2,Sise Meghan E.3,Lim Joseph K.4,Schmidt Monica5,Chung Raymond T.3,Liapakis Annmarie4,Nelson David R.6,Fried Michael W.5,Terrault Norah A.1,

Affiliation:

1. University of California San Francisco; San Francisco CA USA

2. Saint Louis University School of Medicine; St Louis MO USA

3. Massachusetts General Hospital; Boston MA USA

4. Yale University School of Medicine; New Haven CT USA

5. University of North Carolina; Chapel Hill NC USA

6. University of Florida; Gainesville FL USA

Funder

University of Florida

University of North Carolina at Chapel Hill

AbbVie

Bristol-Myers Squibb

Gilead Sciences

Janssen

Kadmon

Merck

Vertex

CTSA UF

National Institutes of Health

UCSF Liver Center member

Publisher

Wiley

Subject

Hepatology

Reference22 articles.

1. AASLD/IDSA/IAS-USA Recommendations for testing, managing, and treating hepatitis C http://www.hcvguidelines.org

2. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease;Tsui;Arch Intern Med,2007

3. Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET;Gordon;J Hepatol,2015

Cited by 262 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3